Literature DB >> 6338264

Oral contraceptive use and the risk of ovarian cancer. The Centers for Disease Control Cancer and Steroid Hormone Study.

.   

Abstract

Since oral contraceptives have been used by more than 40 million American women, an association between oral contraceptives and ovarian cancer could have a substantial public health impact. The Centers for Disease Control, Atlanta, is studying this relationship as part of a multicenter, case-control study--the Cancer and Steroid Hormone Study. During the first ten months of the study, we enrolled 179 women aged 20 to 54 years who had been ascertained to have newly diagnosed ovarian cancer by eight population-based cancer registries. From the general population of those eight areas, we selected as controls 1,642 women with intact ovaries. Users of oral contraceptives had an age-adjusted risk of ovarian cancer developing of 0.6 relative to those who had never used them (95% confidence interval, 0.4 to 0.9). The risk of ovarian cancer decreased with increasing duration of oral contraceptive use and remained low long after cessation of use. These results were not accounted for by parity, infertility, or other potentially confounding factors. We estimate that more than 1,700 cases of ovarian cancer are averted each year by past and current oral contraceptive use among women in the United States.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6338264

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  8 in total

1.  Evaluation of a prescription based record-linkage model for epidemiological studies of long-term adverse effects of drugs--with special regard to combined oral contraceptives.

Authors:  I Persson; H O Adami; S E Norell; B Westerholm; B E Wiholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Preventive medicine and public health: combined oral contraceptives and cancer.

Authors:  D B Thomas
Journal:  West J Med       Date:  1985-11

Review 3.  Management of early carcinoma of the ovary.

Authors:  G W Chapman
Journal:  J Natl Med Assoc       Date:  1988-09       Impact factor: 1.798

Review 4.  The predictive value of steroid hormone receptor analysis in breast, endometrial and ovarian cancer.

Authors:  R Vihko; A Alanko; V Isomaa; A Kauppila
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

Review 5.  Hormonal contraception in adolescents: special considerations.

Authors:  Rollyn M Ornstein; Martin M Fisher
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 6.  Gynecologic cancers associated with Lynch syndrome/HNPCC.

Authors:  K M Schmeler; K H Lu
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

Review 7.  Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer.

Authors:  Elizabeth Swisher
Journal:  Curr Treat Options Oncol       Date:  2003-04

8.  Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.

Authors:  Gina M Mantia-Smaldone; Robert P Edwards; Anda M Vlad
Journal:  Cancer Manag Res       Date:  2010-12-30       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.